Endocr Pract. 2026 Jun 5:S1530-891X(26)01025-6. doi: 10.1016/j.eprac.2026.05.033. Online ahead of print.
ABSTRACT
AIM: To evaluate weight management efficacy of SGLT-2i and GLP-1RA therapy in overweight/obese type 2 diabetes (T2D) patients within a digital shared care model.
METHODS: We conducted a real-world retrospective analysis of 921 patients from a diabetes shared care clinic (2022-2025). Patients were stratified into four groups: SGLT-2i, GLP-1RA, combination therapy, and control. Primary outcomes included changes in body weight, BMI, waist circumference, and HbA1c after median 1.84 years of follow-up. Hierarchical multivariable logistic regression adjusted for baseline characteristics and digital engagement metrics.
RESULTS: Combination therapy achieved the greatest median weight reduction (5.1%; 4.0 kg). GLP-1RA monotherapy showed the largest HbA1c reduction (-1.20%). After adjusting for digital engagement, the odds of ≥5% weight loss in combination group increased by 5.02%. Higher baseline BMI and longer diabetes duration predicted weight loss success, while higher baseline HbA1c was negatively associated.
CONCLUSIONS: SGLT-2i and GLP-1RA combination therapy provides superior weight management in overweight/obese T2D patients, with effects enhanced by digital shared care model.
PMID:42250764 | DOI:10.1016/j.eprac.2026.05.033